about
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancerAfatinib and Erlotinib in the treatment of squamous-cell lung cancerThe role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patientsCIMAvax-EGF, a therapeutic non-small cell lung cancer vaccineADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentariumCorrelation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with NivolumabSerum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot studyRETRACTED ARTICLE: Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label studyBaseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancerNivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosusMicrotubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compoundsTargeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectivesPrecision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable PatientCall for ensuring cancer care continuity during COVID-19 pandemicItalian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreakNew emerging targets in cancer immunotherapy: the role of VISTA
P50
Q38870763-3E524ABA-98B9-416A-B9C2-14E62E1C1DF5Q39226762-012C40D5-7419-4A8F-9D34-03A0D1A7C95BQ55309832-937902FC-8FDA-4F8D-A85F-154E181D4530Q57791418-DE68F3A1-F6DE-4A01-B106-670707FC39B4Q58614043-1D457F3C-3855-4A95-BF9D-DBDC3AE22342Q64115913-80996209-3146-4E4F-B561-641B8189FDD4Q89221328-E16B479D-4AD1-4386-80B1-1D60BEEF6EB9Q89775155-9BD75718-20EC-4E88-AAFC-5A3AA7C41AFDQ90460206-86F783B7-8379-4950-85B9-F3C297D6FFC9Q92051747-41D75C0E-FC61-4BBC-9202-A70E30D5204FQ92164620-873CE960-5C5D-4C26-BCEC-8998AA7A2CE9Q92379849-3E3C64B5-41F1-4745-BC40-98322B1D9D09Q92475730-A8D01140-8E88-41F7-B075-F34D79151ECDQ92496035-D2F79A67-5EA0-40BA-B853-D26096483242Q92516870-941A53DD-F0E6-433D-8202-7F3F829E23D4Q94516033-E5E37FD8-FF8E-4262-B155-B8596336BB33Q94547845-401DD33F-48E5-4296-937C-858F68A03ABDQ96341693-7735B4BA-73BA-46B4-B1F2-7D3D1C1B1622Q96589493-06387873-D286-49C8-93AE-858BB57E7D73
P50
description
researcher
@en
wetenschapper
@nl
name
Marco Tagliamento
@en
Marco Tagliamento
@nl
type
label
Marco Tagliamento
@en
Marco Tagliamento
@nl
prefLabel
Marco Tagliamento
@en
Marco Tagliamento
@nl
P31
P496
0000-0001-7461-023X